Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s share price rose 2.2% on Tuesday . The company traded as high as $21.73 and last traded at $21.42, with a volume of 1,099,296 shares changing hands. The stock had previously closed at $20.95.

SRPT has been the subject of a number of analyst reports. Oppenheimer Holdings Inc. reissued a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, April 21st. WBB Securities reissued a “buy” rating and issued a $40.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, March 30th. Needham & Company LLC reissued a “buy” rating and issued a $20.00 price objective (down from $53.00) on shares of Sarepta Therapeutics in a research report on Sunday, April 24th. Robert W. Baird reissued a “buy” rating and issued a $23.00 price objective (down from $47.00) on shares of Sarepta Therapeutics in a research report on Saturday, April 23rd. Finally, Vetr cut shares of Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating and set a $17.92 price objective for the company. in a research report on Monday, April 25th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $24.17.

The stock’s market cap is $1.03 billion. The company’s 50 day moving average is $19.36 and its 200 day moving average is $18.28.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period in the previous year, the company posted ($0.87) EPS. Equities research analysts forecast that Sarepta Therapeutics Inc. will post ($4.48) EPS for the current fiscal year.

A number of hedge funds and institutional investors have recently made changes to their positions in SRPT. Jennison Associates LLC increased its position in shares of Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock valued at $32,354,000 after buying an additional 689,831 shares during the period. Creative Planning increased its position in shares of Sarepta Therapeutics by 95.7% in the fourth quarter. Creative Planning now owns 52,950 shares of the company’s stock valued at $2,043,000 after buying an additional 25,900 shares during the period. ProShare Advisors LLC increased its position in shares of Sarepta Therapeutics by 20.5% in the fourth quarter. ProShare Advisors LLC now owns 42,922 shares of the company’s stock valued at $1,656,000 after buying an additional 7,301 shares during the period. California State Teachers Retirement System increased its position in shares of Sarepta Therapeutics by 9.7% in the fourth quarter. California State Teachers Retirement System now owns 82,932 shares of the company’s stock valued at $3,200,000 after buying an additional 7,300 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock valued at $1,841,000 after buying an additional 6,615 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.